Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00904683 | Effect of LY2062430 on the Progression of Alzheimer's Disease | PHASE3 | COMPLETED | 1,040 | — | — | May 1, 2009 | Jun 1, 2012 | Dec 13, 2012 | 95 | United States, Australia +11 |
| NCT00905372 | Effect of LY2062430 on the Progression of Alzheimer's Disease | PHASE3 | COMPLETED | 1,000 | — | — | May 1, 2009 | Apr 1, 2012 | Sep 25, 2012 | 85 | United States, Argentina +3 |
| NCT00329082 | Effects of LY2062430 in Subjects With Mild-to-Moderate Alzheimer's Disease and in Healthy Volunteers | PHASE2 | COMPLETED | 25 | — | — | May 1, 2006 | May 1, 2008 | Oct 7, 2009 | 6 | United States |
| Arm | Type | Description |
|---|---|---|
| LY2062430 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| 1 | EXPERIMENTAL | - |
| 2 | EXPERIMENTAL | - |
| 3 | EXPERIMENTAL | - |
| 4 | EXPERIMENTAL | - |
| 5 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| LY2062430 | DRUG | 400 mg intravenously (IV) every 4 weeks for 80 weeks |
| Placebo | DRUG | intravenously (IV) every 4 weeks for 80 weeks |
Inclusion Criteria: * Meets criteria for mild to moderate Alzheimer's Disease (AD) with Mini-Mental State Examination score of 16 through 26 at screening * Modified Hachinski Ischemia Scale score of less than or equal to 4 * Geriatric Depression Scale score of less than or equal to 6 * A magnetic r...